Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Recursion

AI Pharma: 2 Paths to AI-Powered Drug Investment

AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.

NVIDIA Invested in These 2 AI Stocks, Should You?

NVIDIA Invested in These 2 AI Stocks, Should You?

Discover 2 compelling AI stocks NVIDIA (NASDAQ: NVDA) has invested in. Learn how the AI leader's vision can guide your portfolio in the tech revolution.

1 AI Biotech Stock That Just Scored a Major Milestone

1 AI Biotech Stock That Just Scored a Major Milestone

Down over 85% from all-time highs, Recursion Pharmaceuticals is an AI-powered biotech company that aims to accelerate the drug discovery process.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

AI Could Power Up These 2 Biotech Stocks

AI is rapidly transforming the healthcare industry. Evolving companies such as Intuitive Surgical and Recursion Pharmaceuticals can capitalize on this opportunity.

Should You Buy the Dip in This AI-Driven Drug Stock?

Down 76% from all-time highs, is this AI-powered drug stock a good buy right now?

3 Small-Cap Stocks Set To Skyrocket

These under-the-radar companies may offer greater long-term rewards.

3 Small-Cap Stocks to Invest in AI Drug Development

As AI continues to reshape the drug development landscape, here are three promising small-cap biotech stocks worth considering now.

inkl

Read news from The Economist, FT, and more,
with one subscription

1 AI Growth Stock With 54% Upside Potential

1 AI Growth Stock With 54% Upside Potential

Shares of Recursion Pharmaceuticals offer solid upside potential, given the company's trailblazing approach to drug discovery leveraging AI. Here’s a closer look at the biotech stock that has garnered investments from both AI chipmaker Nvidia and ARKK fund manager Cathie Wood.

Nvidia Just Invested $76 Million in 1 Cathie Wood Stock

Nvidia Just Invested $76 Million in 1 Cathie Wood Stock

Along with plowing cash into smaller AI chip stocks, Nvidia also made an outsized bet on this Utah-based biotech company that's a part of Wood's flagship ARKK fund.

Nvidia Just Invested $76 Billion in 1 Cathie Wood Stock

Nvidia Just Invested $76 Billion in 1 Cathie Wood Stock

Along with plowing cash into smaller AI chip stocks, Nvidia also made an outsized bet on this Utah-based biotech company that's a part of Wood's flagship ARKK fund.

1 Cathie Wood Stock With Over 100% Upside, According to Analysts

1 Cathie Wood Stock With Over 100% Upside, According to Analysts

This biotech stock under $10 is the newest addition to Cathie Wood's flagship ARKK fund - and Wall Street analysts have high hopes for the shares, too.

Cathie Wood picks up nearly 2 million shares of struggling, cheap stock

Cathie Wood picks up nearly 2 million shares of struggling, cheap stock

Ark Invest's latest big biotech bet is down 15% for the year.

Cathie Wood snaps up nearly 4 million shares of a surging biotech stock

Cathie Wood snaps up nearly 4 million shares of a surging biotech stock

This stock spiked more than 10% Tuesday.

Three venture investors weigh in on the future of biotech as they launch a new $350M fund

Three venture investors weigh in on the future of biotech as they launch a new $350M fund

Lux Capital and Obvious Ventures veterans have closed a new fund they think can help cure diseases faster.

Get all your
news in one place.

100’s of premium titles.
One news app.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Intuitive Surgical

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

243,844 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play